Germany: Merck stops development of Parkinson's disease treatment

Germany: Merck stops development of Parkinson's disease treatment
Germany: Merck stops development of Parkinson's disease treatment

Darmstadt-based Merck said it decided "not to file for approval and not to pursue further development of the compound," known as Sarizotan, which was intended to treat advanced Parkinson's disease patients suffering from dyskinesia, the AP reports.

The setback comes after Merck lost out to Bayer AG in the race to acquire a third German drug maker, Schering AG.